An evidence-based review of certolizumab pegol in the treatment of active psoriatic arthritis: place in therapy

María Laura Acosta-Felquer, Javier Rosa, Enrique R SorianoRheumatology Unit, Internal Medical Services, and University Institute, Hospital Italiano de Buenos Aires, Buenos Aires, ArgentinaAbstract: Certolizumab pegol (CZP) is a pegylated humanized tumor necrosis factor-α&nbs...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Acosta-Felquer ML, Rosa J, Soriano ER
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	certolizumab pegol tumour necrosis factor alpha inhibitors psoriatic arthritis efficacy safety. Diseases of the musculoskeletal system RC925-935
Acceso en línea:	https://doaj.org/article/e03a92969113483db5c49e04601dd081
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e03a92969113483db5c49e04601dd081
record_format	dspace
spelling	oai:doaj.org-article:e03a92969113483db5c49e04601dd0812021-12-02T04:40:20ZAn evidence-based review of certolizumab pegol in the treatment of active psoriatic arthritis: place in therapy1179-156Xhttps://doaj.org/article/e03a92969113483db5c49e04601dd0812016-03-01T00:00:00Zhttps://www.dovepress.com/an-evidence-based-review-of-certolizumab-pegol-in-the-treatment-of-act-peer-reviewed-article-OARRRhttps://doaj.org/toc/1179-156XMaría Laura Acosta-Felquer, Javier Rosa, Enrique R SorianoRheumatology Unit, Internal Medical Services, and University Institute, Hospital Italiano de Buenos Aires, Buenos Aires, ArgentinaAbstract: Certolizumab pegol (CZP) is a pegylated humanized tumor necrosis factor-α inhibitor (TNFi) approved for the treatment of psoriatic arthritis (PsA) in Europe, the USA, and Latin American countries. CZP neutralizes TNF-α at its soluble and membrane portions. Due to the lack of Fc region, it does not induce complement or antibody-dependent cytotoxicity in vitro, unlike other TNFi. RAPID-PsA study, the only randomized clinical trial performed in PsA, is a Phase III clinical trial conducted in 409 PsA patients during 24 weeks. Patients were randomized to CZP (200 mg every 2 weeks or 400 mg every 4 weeks) or placebo. Patients in CZP arms reported improvements in skin disease, joint involvement, dactylitis, enthesitis, and quality of life. Safety profile was similar to that reported for other TNF-α inhibitors in PsA patients. This article summarizes the pharmacology and reviews the efficacy and tolerability of this drug in PsA. CZP is the newest TNFi with proved efficacy in all manifestations of psoriasis disease, except for axial involvement where the evidence has been derived from response to axial spondyloarthritis.Keywords: certolizumab pegol, tumor necrosis factor- inhibitors, psoriatic arthritis, efficacy, safetyAcosta-Felquer MLRosa JSoriano ERDove Medical Pressarticlecertolizumab pegoltumour necrosis factor alpha inhibitorspsoriatic arthritisefficacysafety.Diseases of the musculoskeletal systemRC925-935ENOpen Access Rheumatology: Research and Reviews, Vol 2016, Iss Issue 1, Pp 37-44 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	certolizumab pegol tumour necrosis factor alpha inhibitors psoriatic arthritis efficacy safety. Diseases of the musculoskeletal system RC925-935
spellingShingle	certolizumab pegol tumour necrosis factor alpha inhibitors psoriatic arthritis efficacy safety. Diseases of the musculoskeletal system RC925-935 Acosta-Felquer ML Rosa J Soriano ER An evidence-based review of certolizumab pegol in the treatment of active psoriatic arthritis: place in therapy
description	María Laura Acosta-Felquer, Javier Rosa, Enrique R SorianoRheumatology Unit, Internal Medical Services, and University Institute, Hospital Italiano de Buenos Aires, Buenos Aires, ArgentinaAbstract: Certolizumab pegol (CZP) is a pegylated humanized tumor necrosis factor-α inhibitor (TNFi) approved for the treatment of psoriatic arthritis (PsA) in Europe, the USA, and Latin American countries. CZP neutralizes TNF-α at its soluble and membrane portions. Due to the lack of Fc region, it does not induce complement or antibody-dependent cytotoxicity in vitro, unlike other TNFi. RAPID-PsA study, the only randomized clinical trial performed in PsA, is a Phase III clinical trial conducted in 409 PsA patients during 24 weeks. Patients were randomized to CZP (200 mg every 2 weeks or 400 mg every 4 weeks) or placebo. Patients in CZP arms reported improvements in skin disease, joint involvement, dactylitis, enthesitis, and quality of life. Safety profile was similar to that reported for other TNF-α inhibitors in PsA patients. This article summarizes the pharmacology and reviews the efficacy and tolerability of this drug in PsA. CZP is the newest TNFi with proved efficacy in all manifestations of psoriasis disease, except for axial involvement where the evidence has been derived from response to axial spondyloarthritis.Keywords: certolizumab pegol, tumor necrosis factor- inhibitors, psoriatic arthritis, efficacy, safety
format	article
author	Acosta-Felquer ML Rosa J Soriano ER
author_facet	Acosta-Felquer ML Rosa J Soriano ER
author_sort	Acosta-Felquer ML
title	An evidence-based review of certolizumab pegol in the treatment of active psoriatic arthritis: place in therapy
title_short	An evidence-based review of certolizumab pegol in the treatment of active psoriatic arthritis: place in therapy
title_full	An evidence-based review of certolizumab pegol in the treatment of active psoriatic arthritis: place in therapy
title_fullStr	An evidence-based review of certolizumab pegol in the treatment of active psoriatic arthritis: place in therapy
title_full_unstemmed	An evidence-based review of certolizumab pegol in the treatment of active psoriatic arthritis: place in therapy
title_sort	evidence-based review of certolizumab pegol in the treatment of active psoriatic arthritis: place in therapy
publisher	Dove Medical Press
publishDate	2016
url	https://doaj.org/article/e03a92969113483db5c49e04601dd081
work_keys_str_mv	AT acostafelquerml anevidencebasedreviewofcertolizumabpegolinthetreatmentofactivepsoriaticarthritisplaceintherapy AT rosaj anevidencebasedreviewofcertolizumabpegolinthetreatmentofactivepsoriaticarthritisplaceintherapy AT sorianoer anevidencebasedreviewofcertolizumabpegolinthetreatmentofactivepsoriaticarthritisplaceintherapy AT acostafelquerml evidencebasedreviewofcertolizumabpegolinthetreatmentofactivepsoriaticarthritisplaceintherapy AT rosaj evidencebasedreviewofcertolizumabpegolinthetreatmentofactivepsoriaticarthritisplaceintherapy AT sorianoer evidencebasedreviewofcertolizumabpegolinthetreatmentofactivepsoriaticarthritisplaceintherapy
_version_	1718401156602920960

An evidence-based review of certolizumab pegol in the treatment of active psoriatic arthritis: place in therapy

Ejemplares similares